Back to Search

NEIL SENZER, MD

MD

Radiation Oncology Physician

NPI: 1255379236Individual

Specialties, Licenses & Credentials

Radiation Oncology PhysicianPrimary

Radiology — Radiation Oncology

Code: 2085R0001X

G7720(TX)

Research & Publications (20)

A review of contusugene ladenovec (Advexin) p53 therapy.
PMID 19169960·Curr Opin Mol Ther·2009
6-review
p53 therapy in a patient with Li-Fraumeni syndrome.
PMID 17483435·Mol Cancer Ther·2007
5-case
Individualised cancer therapeutics: dream or reality?
PMID 16300470·Expert Opin Ther Targets·2005
6-review
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial.
PMID 15685033·Am J Clin Oncol·2005
3-trial
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
PMID 14726502·J Clin Oncol·2004
3-trial
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
PMID 12577242·Semin Oncol·2002
3-trial
Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation.
PMID 12577244·Semin Oncol·2002
6-review
Prostate cancer: multimodality approaches with docetaxel.
PMID 11685734·Semin Oncol·2001
6-review
MicroRNA profile analysis of human prostate cancers.
PMID 18949015·Cancer Gene Ther·2009
8-other
Systemic therapeutic gene delivery for cancer: crafting Paris' arrow.
PMID 19275571·Curr Gene Ther·2009
6-review
Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.
PMID 19287371·Cancer Gene Ther·2009
3-trial
siRNA vs. shRNA: similarities and differences.
PMID 19389436·Adv Drug Deliv Rev·2009
6-review
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
PMID 19643020·BMC Cancer·2009
3-trial
Transcription factors: their potential as targets for an individualized therapeutic approach to cancer.
PMID 18846113·Cancer Gene Ther·2009
6-review
Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.
PMID 19501491·Clin Oncol (R Coll Radiol)·2009
3-trial
Stathmin 1: a novel therapeutic target for anticancer activity.
PMID 18759697·Expert Rev Anticancer Ther·2008
6-review
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
PMID 18802154·J Clin Oncol·2008
3-trial
Proof concept for clinical justification of network mapping for personalized cancer therapeutics.
PMID 17541424·Cancer Gene Ther·2007
8-other
A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients.
PMID 17704755·Cancer Gene Ther·2007
3-trial
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review).
PMID 17912425·Int J Oncol·2007
6-review

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3410 WORTH ST
DALLAS, TX 75246

Location

Practice Location

3410 WORTH ST, DALLAS, TX
(214) 370-1400

Quick Facts

NPI
1255379236
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile